Merkle Capital this week rolled out what it calls Asia’s first regulated fund dedicated to Injective’s INJ token. The move is aimed squarely at institutional investors who've been cautious about crypto exposure without a regulated wrapper. It's a narrow product for now — just one token — but it signals how asset managers are trying to bridge traditional finance and digital assets.
What the fund actually does
The fund is structured as a regulated vehicle, meaning it must follow local securities laws and report to the relevant regulator — Merkle Capital didn't name which one. It offers accredited investors direct exposure to INJ, the native token of the Injective blockchain, which focuses on decentralized derivatives. The launch highlights a growing push to package individual tokens into compliant funds rather than forcing institutions to buy spot or use unregulated platforms.
Why institutions might care
Institutional adoption in crypto has mostly come through ETFs for Bitcoin and Ethereum, or through venture-style funds that invest in a basket of tokens. Single-token regulated funds are rarer, especially for smaller-cap assets like INJ. Merkle Capital is betting that some allocators want targeted bets on specific protocols but won't touch unregulated products. If that works, it could open the door for similar funds tied to other Layer-1 or DeFi tokens.
The risks that come with the structure
Merkle Capital acknowledged in its announcement that the fund carries inherent market risks — INJ’s price volatility, liquidity constraints, and regulatory uncertainty are all factors. A regulated fund doesn't eliminate those risks; it just means the manager has to follow custody, reporting, and disclosure rules. For investors, the trade-off is transparency and compliance versus the freedom of unregulated DeFi exposure.
What happens next
Merkle Capital hasn't disclosed a target raise or a start date for subscriptions. Rival firms are likely watching closely — if the fund draws meaningful inflows, more single-token regulated products will probably follow. The real test will be whether institutions bite. No word yet on a second fund, but the template is there.
